Androgen Induces Adaptation to Oxidative Stress in Prostate Cancer: Implications for Treatment with Radiation Therapy  by Pinthus, Jehonathan H. et al.
Androgen Induces Adaptation to Oxidative Stress in Prostate
Cancer: Implications for Treatment with Radiation Therapy1
Jehonathan H. Pinthus*,y,z, Inna Bryskin y, John Trachtenberg*, Jiang-Ping Lu z, Gurmit Singh§,
Eduard Fridman z and Brian C. Wilson y
*The Prostate Cancer Center, University Health Network, Toronto, Ontario, Canada; yDepartment of Medical
Biophysics, Ontario Cancer Institute/University of Toronto, Toronto, Ontario, Canada; Departments of zSurgery and
§Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
Abstract
Radiation therapy is a standard treatment for prostate
cancer (PC). The postulated mechanism of action for
radiation therapy is the generation of reactive oxygen
species (ROS). Adjuvant androgen deprivation (AD)
therapy has been shown to confer a survival advantage
over radiation alone in high-risk localized PC. How-
ever, the mechanism of this interaction is unclear. We
hypothesize that androgens modify the radiorespon-
siveness of PC through the regulation of cellular oxi-
dative homeostasis. Using androgen receptor (AR)+
22rv1 and AR PC3 human PC cell lines, we demon-
strated that testosterone increased basal reactive oxy-
gen species (bROS) levels, resulting in dose-dependent
activation of phospho-p38 and pAKT, and increased ex-
pression of clusterin, catalase, and manganese super-
oxide dismutase. Similar data were obtained in three
human PC xenografts; WISH-PC14, WISH-PC23, and
CWR22, growing in testosterone-supplemented or cas-
trated SCIDmice. These effectswere reversible through
AD or through incubation with a reducing agent. More-
over, testosterone increased the activity of catalase,
superoxide dismutases, and glutathione reductase.
Consequently, AD significantly facilitated the response
of AR+ cells to oxidative stress challenge. Thus, testos-
terone induces a preset cellular adaptation to radia-
tion through the generation of elevated bROS, which
is modified by AD. These findings provide a rational
for combined hormonal and radiation therapy for lo-
calized PC.
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Introduction
In 2005, there were an estimated 234,460 new cases of
prostate cancer (PC) diagnosed in the United States, and
27,350 men succumbed to this disease [1]. Widespread
prostate-specific antigen (PSA) screening has led to earlier
diagnosis of PC. Radiation is a common viable treatment
option for localized PC. However, substantial heterogeneity
in patient response to radiation exists. Using the current regi-
men of high-dose conformal radiation, treatment failure occurs
in 45% of patients with locally confined disease [2]. It is likely
that, in addition to individual patient risk factors, intrinsic dif-
ferences in cellular radiosensitivity exist, explaining the diver-
sity in responses. Escalating the dose of radiation to ultrahigh
levels is one experimental approach used to overcome treat-
ment failure. Although treatment outcome directly correlates
with risk factors such as PSA,Gleason score, and clinical stage,
radiation dose escalation improves cancer control even for
intermediate-risk to high-risk patients [3]. However, results are
still unsatisfactory, and an increased rate of rectal toxicity has
been reported [3,4].
Combining radiation therapy and androgen deprivation (AD)
therapy is another tactic used to combat treatment failure.
Several phase 3 randomized controlled trials demonstrated
an overall survival benefit for patients with locally advanced
disease who received combined radiation and AD compared
to patients who received radiation alone [5–7]. Neverthe-
less, the specific contribution of AD therapy in the majority of
intermediate-risk PC patients remains controversial [8]. From a
clinical perspective, there is concern that the net benefit of
the combined approach stems mainly from hormonal effects
per se. It is also unknown whether AD therapy obviates the
need for dose escalation or whether it is even necessary when
higher radiation doses are used. Unfortunately, adequately
powered trials, which are designed to address these issues,
have not been reported. The potential of AD therapy for cyto-
reduction and control of micrometastatic disease has been pos-
tulated [9]. In vivo studies using androgen-sensitive Shionogi
tumors illustrate that overall cell killing increases when AD is
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added to radiation [10]. In vitro, androgens were shown to
block apoptosis induced by the combination of Fas antibodies
or tumor necrosis factor a (TNFa) and irradiation in LNCaP
PC cells [11]. Furthermore, AD therapy may facilitate radia-
tion through its antiangiogenic effect [12] and through the
reduction of HIF-1a levels [13], which has been shown ex-
perimentally to increase in vitro radiosensitivity in HCT116
and PC3 tumors [14].
In this study, we examined a novel mechanism by which
androgens may play a role in the therapeutic effect of
radiation on PC. We examined cellular sensitivity to oxida-
tive stress challenge in the presence and in the absence
of androgens.
The major therapeutic feature of radiation is the induction
of toxic oxidative damage in targeted cancer cells. Reactive
oxygen species (ROS) are generated from cellular water
by high-energy deposition during radiation. These free radi-
cals mediate multilevel cell injury: disruption of plasma,
mitochondrial, nuclear, and endoplasmic reticulum mem-
branes by lipid peroxidation, and induction of protein cross
links, leading to increased membrane permeability and loss
of function. ROS oxidize amino acid residues (mainly cyste-
ine), altering normal protein function and degradation pro-
cesses. Most importantly, ROS oxidize mitochondrial and
nuclear DNA, resulting in strand breaks. However, ROS are
formed constantly as byproducts of normal enzymatic meta-
bolic reactions. Thus, to prevent overwhelming oxidative
damage, cells maintain a basal redox balance between pro-
oxidative and antioxidative reactions.
Despite numerous studies on androgens and PC, there
have been few reports on the effects of AD on oxidative stress
in PC cells. Ripple et al. [15] demonstrated that physiological
levels of androgens are capable of increasing oxidative
stress in LNCaP cells, and they suggested that this is partly
due to increasedmitochondrial activity. Interestingly, Sun et al.
[16] postulated that PSA, rather than testosterone, is the fac-
tor responsible for the effect of testosterone on ROS gener-
ation because the androgen receptor (AR) blocker flutamide,
as well as anti-PSA antibody, can block the effect. These
studies have not been reported using PC patient samples.
Serum testosterone levels in the aging PC patient popu-
lation widely vary. From the fourth decade, a period believed
to be related to PC initiation and progression [17], circulating
testosterone levels start to drop significantly [18]. It has been
shown that androgen levels affect individual tumor pheno-
types differently [19]. This finding may indicate that a pa-
tient’s own androgenic milieu models his individual tumor
features and response to therapy.
In this study, we examined the hypothesis that AD sensi-
tizes PC cells to oxidative stress, thereby enhancing radiation
response. We demonstrate that, in the presence of andro-
gens, AR-expressing human PC cells acquire relative resis-
tance to oxidative stress. This adaptation process stems
from the fact that androgens increase basal reactive oxygen
species (bROS) levels. In turn, this stimulates the activation
and the expression of stress molecules and antioxidative
enzymes to better cope with the shift in redox balance. Then,
on subsequent challenges with oxidative stress–based
therapies, such as radiation or photodynamic therapy, these
cells become less sensitive to toxic levels of ROS compared
to androgen-deprived cells and are, therefore, less sus-
ceptible to treatment.
Materials and Methods
Cell Lines and Xenografts
Both 22rv1 and PC3 human PC cell lines were purchased
from the American Type Culture Collection (Manassas, VA)
and cultured at 37jC in a humidified atmosphere under 5%
CO2 in air. The 22rv1 culture medium consisted of phenol
red-free RPMI 1640 with 2 mM L-glutamine adjusted to
contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM
HEPES, 1.0 mM sodium pyruvate, and 10% charcoal-stripped
fetal calf serum (CSFCS). PC3 culture medium was com-
posed of phenol red-free DMEM with 2 mM L-glutamine ad-
justed to contain 1.5 g/l sodium bicarbonate and 10%CSFCS.
CWR22 [20], WISH-PC14, andWISH-PC23 [21] human pros-
tate adenocarcinomas were grown as subcutaneous xeno-
grafts in SCID mice within the SPC colony of the Weizmann
Institute of Science, in compliance with institutional guide-
lines. Prof. Eshhar (Weizmann Institute of Science) provided
paraffin blocks of LuCAP-35 xenografts grown in castrated
and testosterone-supplemented male SCID mice [22].
Hormonal Treatments
In vitro Cells were grown in an androgen-depleted me-
dium composed of phenol-free medium and 10% CSFCS.
The normal values for testosterone in the serum of adult
males are 14 to 35 nM. Thus, testosterone (R1881; Sigma,
St. Louis, MO) was added to a final concentration of 1010
to 108 M to create an androgen-supplemented medium. To
block the effects of testosterone, the AR blocker bicalutamide
(AstraZeneca, Macclesfield Cheshire, UK) was added to a fi-
nal concentration of 105 M, mimicking the mean plasma con-
centration (50.2 mM) in PC patients treated with bicalutamide
monotherapy (150 mg daily) [23]. In several experiments,
105 M bicalutamide was added to the androgen-depleted
medium to exclude the effects of the drug itself. To induce
different hormonal effects, cells were preincubated in these
media for 48 to 72 hours before further manipulation.
In vivo To induceADor androgen supplementation, tumors
were grown in 7- to 10-week-old male mice (CB.17-SCID
BEIGE) that underwent bilateral orchiectomy or that were
transplanted subcutaneously with 90-day slow-release tes-
tosterone pellets (12.5 mg/pellet; Innovative Research of
America, Sarasote, FL), as previously described [24].
Measurement of Global Metabolic Activity
WST-1 assay (Roche, Quebec, Canada) was used to
assess cellular metabolic activity according to the manufac-
turer’s instructions.
Detection of bROS In Vitro
We used two methods for the detection of bROS.
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Nitroblue tetrazolium (NBT) assay Cells were grown to
confluence in 96-well plates. R1881 and/or bicalutamide
was added 48 hours before the experiments. ROS produc-
tion was detected by NBT assay (Sigma). NBT is a yellow
water-soluble powder that, on reduction by ROS, changes
to dark-blue insoluble formazan. Cells were incubated for
90 minutes in phosphate-buffered saline (PBS) containing
0.1% NBT. Formazan was dissolved by sonication in 50%
acetic acid, and optical absorbance was determined at
560 nm. After the subtraction of assay blanks, the results
were normalized to the metabolic activity of cells in each hor-
monal condition, as determined by WST-1 assay.
Confocal microscopy 22rv1 cells were grown in a cell
culture for 72 hours under different hormonal conditions, as
specified above. The cells were then either incubated or
not incubated with 5 mM NAC (Sigma) for 3 hours, fol-
lowed by PBS wash and trypsinization. Equal numbers of
cells were then placed onto glass cover slips at a density of
103 cells/ml. After 24 hours, the cells were loaded with
5 mM dihydroethidium (DHE; Molecular Probes, Burlington,
Ontario, Canada) for 30 minutes at 37jC. After two PBS
washes, fresh medium was added. DHE is oxidized by ROS
to yield ethidium, the fluorescence of which was measured
with a Zeiss SM510 confocal fluorescence microscope
(Carl Zeiss, Toronto, Ontario, Canada; excitation = 475 nm,
emission = 610 nm). Images were analyzed with Image Pro
software (Media Cybernetics, Silver Spring, MD). The re-
sults were expressed as mean ±1 SD after background sub-
traction and normalization to metabolic activity, as above.
Immunoblot assays Cells were grown to subconfluence
under the different hormonal conditions described above.
When indicated, cells were preincubated with H2O2 at 1 mM
for 30 minutes. After two washes with ice-cold PBS, cells
were lysed in a 1% Triton X-100/PBS lysis buffer supple-
mented with antiproteases and antiphosphatases cocktail
(Sigma) for 30 minutes at 4jC. Centrifuging at 12,000g for
15 minutes separated insoluble materials. Supernatants
were dissolved in Laemmli sample buffer. Protein puri-
fication from tumor tissues was performed using a pro-
tein extraction kit (Biochain Institute, Inc., Greenland, NH).
Equivalent amounts of protein (30–50 mg) were resolved by
sodium dodecyl sulfate–polyacrylamide electrophoresis in
8% to 12% gels (80 V for 20 minutes; 100 V for 1 hour) and
transferred by electroblotting (1.5 hours at 100 V) to a PVDF
membrane. After blocking nonspecific binding using Tris-
buffered saline (TBS) containing 0.05% Tween-20 (TBS-T)
and 5% nonfat powdered milk, the blot was incubated with
primary antibody against p38 (1:1000; Sigma); phospho-p38
(pp38) (1:1000; Sigma); phospho-AKT(ser473) (1:1000; Cell
Signaling, Danvers, MA); anti-global AKT (1:1000; Cell Sig-
naling); mouse anti–4-hydroxynoneal (4-HNE) (1:10; Oxis,
Inc., Foster City, CA); rabbit anti-catalase (1:2000; Chemicon
International, Temecula, CA); rabbit anti–manganese super-
oxide dismutase (MnSOD), DD-17 (1:1000; Sigma); rabbit
anti-HSP27, H-77 (1:250; Santa Cruz Biotechnology, Santa
Cruz, CA); mouse anti-HSP70 (1:1000; Santa Cruz Bio-
technology); mouse anti-HSP90 (1:1000; StressGen Bio-
technologies, Ann Arbor, MI); and rabbit anti-clusterin,
H-330 (1:100; Santa Cruz Biotechnology) in TBS–5% bovine
serum albumin (BSA) at 4jC overnight or at room tempera-
ture for 1 hour. The membrane was then washed multiple
times with TBS-T and incubated with appropriate horse-
radish peroxidase–conjugated secondary antibodies: goat
anti-mouse or goat anti-rabbit (Sigma), both at 1:1000 dilu-
tion for 1 hour at room temperature. Protein–antibody com-
plexes were detected with an enhanced chemiluminescence
kit (Amersham, Arlington Heights, IL) according to the man-
ufacturer’s recommended protocol. All quantifications of
Western blot analysis were performed by reprobing the
blots with 1:1000 mouse anti–b-actin antibodies (Sigma)
to ensure equal protein loading, followed by scanning
and densitometry using Quantity-One software (Bio-Rad,
Hercules, CA).
Neutral Red Viability Assay
Cells were seeded in triplicate in 96-well plates. After
24 hours of treatment with H2O2 at different concentrations
(200–1500 mM), the cells were incubated for 2 hours with
neutral red (Sigma) diluted to a final concentration of 40 mg/ml
in the medium. Cells were rinsed with fixation solution con-
sisting of 0.5% formaldehyde and 0.1% CaCl2. After a quick
wash with PBS, the cells were treated with extraction solu-
tion (1% glacial acetic acid and 50% ethanol) for 10 minutes
at room temperature. Absorbance was measured by a scan-
ning multiwell spectrophotometer ELISA reader (Tecan Sys-
tems, San Jose, CA) using an excitation of 570 nm. After the
subtraction of assay blanks, the results for each hormonal
condition were expressed as the mean ± 1 SD of the H2O2
concentration that induced 10%, 20%, or 30% cell deaths
relative to cells that were not incubated with H2O2 (for each
hormonal condition).
Clonogenic Radiation Assay
Clonogenic radiation assay (0–4 Gy) with 22rv1 cells that
were hormonally pretreated for 48 hours was performed as
previously described [25].
pAKT and p38 Activity Assays
pAKT and pp38 kinase activities were determined using
specific nonradioactive kits (Cell Signaling) according to
the manufacturer’s instructions. Briefly, whole-cell lysates
were immunoprecipitated overnight at 4jC with immobilized
anti-AKT or anti-pp38 primary antibodies. For pAKT kinase
assay, cell lysates/immobilized antibodies were incubated
for 30 minutes at 30jC with ATP/GSK-3 fusion protein. For
p38 kinase assay, cell lysates/immobilized antibodies were
incubated for 30 minutes at 30jC with ATP/ATF-2 fusion
protein. Reactions were terminated by adding sodium
dodecyl sulfate sample buffer and by heating to 95jC for
5 minutes. Samples were then subjected to Western blot
analysis, as described above. Blots were developed using
anti–phospho-GSK-3 a/b primary antibody to determine
pAKT activity and using anti–phospho-ATF-2 primary anti-
body to determine pp38 activity.
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Immunohistochemistry
Paraffin-embedded formalin-fixed human PC xenograft
samples from testosterone-supplemented or castrated SCID
mice (WISH-PC14, WISH-PC23, and LuCAP-35) were pre-
treated with proteinase K (DakoCytomation, Glostrup, Den-
mark) for 5 minutes at room temperature and washed with
PBS-T. Samples were blocked in 10% normal rabbit serum
(Sigma-Aldrich, St. Louis, MO) diluted in 2% BSA-T for
30 minutes before 1 hour of incubation with goat anti–8-
hydroxy-2V-deoxyguanosine (8-OHdG) antibodies (1:200;
Chemicon International). Detection was performed with bio-
tinylated rabbit anti-goat IgG antibodies (1:500; Vector Lab-
oratories, Burlingame, CA), followed by the suppression of
endogenous peroxidase activity with 30% H2O2 solution,
wash with PBS-T (2), incubation with ABC reagent (Vector
Laboratories), and development with Vector NovaRED Sub-
strate Kit (Vector Laboratories). Slides were counterstained
with hematoxylin and eosin (Sigma-Aldrich).
Superoxide Dismutase (SOD) Activity Assay
SOD activity was measured with a commercial assay
(BIOXYTECH SOD525; Oxis, Inc.). Cell lysates from 22rv1
cells growing for 72 hours in 75-cm2 flasks in the presence
of 108 M R1881 with or without 105 M bicalutamide or with-
out hormonal manipulation (control) were prepared without
using proteinase inhibitors in the lysate buffer and were
then subjected to the assay in accordance with the manu-
facturer’s protocol.
Catalase Activity Assay
Lysates from 22rv1 cells growing in 75-cm2 flasks in
the presence of 108 M R1881 with or without 105 M
bicalutamide or without hormonal manipulation (control) for
72 hours were tested for catalase activity with a commer-
cial kit, in accordance with the manufacturer’s instructions
(Cayman Chemicals, Ann Arbor, MI).
Glutathione Reductase (GR) Activity Assay
GRactivity was analyzed bymeasuring the rate of NADPH
oxidation to NADp+, accompanied by a change in absor-
bance at 340 nm proportional to GR activity. A commercial
GR activity kit (Cayman Chemicals) was used according to
the manufacturer’s instructions.
Global Antioxidative Capacity Assays
The total antioxidative potential of 22rv1 cells following
72 hours of preconditioning under different hormonal manip-
ulation was examined using two calorimetric assays ac-
cording to the manufacturer’s instructions. BIOXYTECH
AOP-490 assay (Oxis, Inc.) measures the reduction of Cu2+
to Cu+ by the combined action of all antioxidants present in
the sample, whereas ImAnOx assay (ALPCO Diagnostics,
Salem, NH) measures the reaction of antioxidants in the
sample with a defined amount of exogenously provided
H2O2, with residual H2O2 depending inversely on antioxida-
tive capacity. All measurements were then normalized to the
metabolic activity of individual samples usingWST-1 assay to
control for potential bias stemming from the difference in
metabolic activity caused by different hormonal stimulations.
Data Analysis
Normally distributed data were analyzed using analysis of
variance (ANOVA). When needed, Box-Cox transformation
was used to reach normality. Differences between cells
treated with androgen supplementation and cells treated with
AD or controls were tested by two-sided Student’s t test and
Dunnett’s test at the 5% significance level. One-way ANOVA
with ‘‘Cell’’ factor was employed for NBTand DHE data. Two-
way ANOVA with ‘‘Cell’’ and ‘‘Treatment’’ factors and Cell 
Treatment interaction term was employed for neutral red
viability experiments and clonogenic survival of data. These
results were confirmed by secondary nonparametric analy-
sis using Mann-Whitney test (CT = control cells growing in a
culturemediumwith CSFCS and without phenol red; T = cells
growing in the same medium but with the addition of 10 nM
R1881; T + B = cells growing in the same medium but with
the addition of both 10 nM R1881 and 10 mM bicalutamide;
results are derived from at least three experiments and are
expressed as mean ± SD).
Results
Effect of AD on Oxidative Stress Response
To avoid bias stemming from the removal of essential
growth factor, 22rv1 human PC cells that express the AR and
manifest androgen responsiveness without growth depen-
dency were selected as prototypes for all our in vitro experi-
ments. We first attempted to test whether androgen
supplementation (within the serum range of adult males,
f 108 M) have a protective effect against oxidative stress
challenge. We initially challenged the cells directly with toxic
levels of H2O2 and determined their survival using neutral
red viability assay. Following 24 hours of incubationwithH2O2
at different doses (200–1500 mM), 22rv1 cells precondi-
tioned with 108 M R1881 were found to be significantly more
resistant than control cells grown in the absence of R1881
(P < .05) (Figure 1A). The addition of bicalutamide to the
conditioned medium partially restored sensitivity (P < .05).
We then exposed the cells to g-radiation using a single
dose of 1 to 4 Gy, representative of the 1.8- to 2-Gy daily
clinical fraction given during curative radiation. Except for the
1-Gy radiation dose, preconditioning with R1881 induced a
significant protective effect (P < .001) (Figure 1B). Again, the
addition of bicalutamide significantly restored the radiosensi-
tivity of cells grown in the presence of R1881 (P < .001).
These results suggest that the relative resistance to
oxidative challenge that androgens conferred in 22rv1 cells
is induced through the AR because coincubation with both
R1881 and bicalutamide could reverse the effect.
Effect of Androgens on bROS
To determine the primary effect of androgens on the
generation of ROS, we first measured ROS levels in 22rv1
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cells treated with increasing doses of R1881. To avoid po-
tential misinterpretation of the net effects of androgens on
the production of ROS, as androgens act as prime growth
factors in androgen-responsive and androgen-dependent
PC cells (hence inducing metabolic activity higher than that
of androgen-deprived cells), ROS measurements were nor-
malized to the metabolic activity of cells under different
hormonal manipulations. We found that treatment of 22rv1
cells with R1881 increased bROS levels in a dose-dependent
manner (Figure 2A). Bicalutamide could significantly block
this phenomenon at all levels of R1881 supplementation used
(P < .05). The highest levels of bROS were recorded in cells
supplemented with 108 M R1881, equivalent to the serum
range of adult males.
We then elected to use 108 M R1881 to further test
whether the increased induction of bROS following androgen
stimulation is AR-mediated. It was found that R1881 could
increase bROS only in PC cells expressing the AR. This
was demonstrated by two assays: NBT reduction (Figure 2B)
and fluorescent staining with DHE that is oxidized by ROS to
yield fluorescence (Figure 2C). R1881 had no effect on bROS
levels in PC3 cells not expressing the AR (Figure 2B).
Moreover, the addition of bicalutamide to R1881 signifi-
cantly reduced (P = .01) the bROS level (Figure 2, B and C)
in 22rv1 cells to an extent similar to that obtained in cells not
treated with R1881 or in cells treated with bicalutamide only
(Figure 2C). Collectively, these results demonstrate that an-
drogens induce elevated levels of bROS in an AR-dependent
manner, independent of increased metabolic rate. Androgen
depletion of the culture medium prevents increased bROS
levels, whereas AR blockade (bicalutamide) can reverse this
phenomenon in cells supplemented with R1881.
To further validate that the increase in bROS is androgen-
regulated not only in vitro and in a singlemodel, we confirmed
in vivo that the androgenic milieu of the host dictates the
basal redox status, using three models of human PC. This
Figure 1. Androgens induce relative resistance to oxidative stress challenge
in 22rv1 human PC cells that can be reversed by AD. (A) Survival of 22rv1
cells in response to 24 hours of incubation with increasing doses of hydrogen
peroxide, as determined by neutral red viability assay. LD = lethal dose. (B)
Survival of 22rv1 cells in response to c-radiation, as determined by colony
formation assay. CT = control cells growing in a culture medium with CSFCS
and without phenol red; T = cells growing in the same medium but with the
addition of 10 nM R1881; T + Bic = cells growing in the same medium but
with the addition of both 10 nM R1881 and 10 M bicalutamide. Results are
derived from at least three experiments and are expressed as mean ± SD.
Figure 2. Androgens increase bROS levels in an AR-dependent manner. (A)
Dose-dependent effect of R1881 on ROS levels in 22rv1 cells, as measured
by NBT reduction assay. Addition of 10 M bicalutamide antagonizes this
effect. (B) The androgen-induced increase in bROS, as measured by NBT
reduction assay, is evident only in PC cells expressing the AR (22rv1), and
not in PC3 cells not expressing the AR. (C) Upper figure: DHE fluorescence
measurements (representative microscopic view of the DHE fluorescence of
22rv1 cells in the presence and in the absence of R1881 and/or bicalut-
amide). Lower figure: Quantification of bROS levels (as measured by confo-
cal fluorescent microscopy) following normalization to cells’ metabolic activity
(measured using WST-1 assay) under different hormonal manipulations.
CT = control cells growing in a culture medium with CSFCS and without
phenol red; T = cells growing in the same medium but with the addition of
10 nM R1881; T + Bic = cells growing in the same medium but with the
addition of both 10 nM R1881 and 10 M bicalutamide. Results are derived
from at least three experiments and are expressed as mean ± SD.
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showed that tumors grown in the absence of endogenous
or exogenous androgens had a reduced expression of
peroxidation-induced 4-HNE protein adducts compared to
tumors growing in the presence of continuous testosterone
supplementation (Figure 3A). These adducts are formed as a
result of covalent links with highly reactive aldehydes such
as 4-HNE that are generated by lipid peroxidation of poly-
unsaturated fatty acids, correlating with the oxidative status
of the cells. Similarly, human PC xenografts growing in male
SCID mice supplemented with testosterone had intense
staining for 8-OHdG compared to the same tumors growing
in castrated animals (Figure 3B). This staining identifies
modified DNA formed by attacks of hydroxyl radicals.
Effect of Androgens on the Expression and Activity
of Stress-Related Molecules
The adaptive response of cells to oxidative stress, in
general, and to radiation, in particular, involves the induction
of a set of proteins and signaling molecules that help combat
further challenge [26]. Therefore, we elected to examine
the effects of androgen supplementation at different doses
versus AD on intracellular levels of several key stress mole-
cules that had been previously linked to adaptive response
to oxidative stress–based therapies [26,27]. Accordingly, the
activated form of AKT–pAKT(ser473) was significantly up-
regulated by R1881 compared to cells that were grown in the
absence of R1881 (P = .004) or in the presence of the com-
bination of R1881 and bicalutamide (P = .03) (Figure 4A).
These differences were accentuated when the cells were
stimulated with toxic doses of ROS following hormonal pre-
conditioning. 22rv1 cells grown in the presence of 108 M
R1881 and subsequently exposed to 1 mM H2O2 expressed
significantly higher levels of the activated form of AKT1
than cells that were preconditioned with 105 M bicalutamide
(P = 4  105) or with the combination of 108 M R1881 and
105 M bicalutamide (P = .007). We clearly demonstrate
that the expression levels of pAKT(ser473) were increased
with androgen supplementation; we did not, however, ob-
serve increased kinase activity.
We found that the activated form of p38 (pp38) was also
significantly upregulated by R1881 compared to cells that
were grown in the absence of R1881 (P = .004) or in the
presence of the combination of R1881 and bicalutamide
(P = .04) (Figure 4B). As in the case of pAKT expression,
exposure to toxic levels (1 mM) of H2O2 following androgen
preconditioning heightened the expression of pp38 (Fig-
ure 4B). Moreover, the catalytic activity of pp38 was sig-
nificantly increased by R1881 (P = .0001) and was inhibited
by the addition of bicalutamide (P = .0001) (Figure 4C).
It has been previously suggested that clusterin, a molec-
ular chaperone, might contribute to resistance to oxidative
stress–mediated damage, especially in the presence of
androgens [28]. We therefore examined the expression of
clusterin in cells either deprived of androgen or treated with
R1881 in the presence or in the absence of bicalutamide.
Androgen increased the expression of clusterin in a dose-
dependent manner, which could be reduced to control levels
by the addition of bicalutamide (Figure 4D). Clusterin expres-
sion was significantly higher in 22rv1 cells preconditioned
with 109 or 108 M R1881 than in cells grown also in the
presence 105 M bicalutamide (P = .003 and P = .04, re-
spectively). No effect of androgen supplementation or AD on
the expression of clusterin was seen in PC3 cells not ex-
pressing the AR (data not shown), further supporting the
androgen-regulated expression of this stress protein. In vivo,
compared to tumors grown in castrated hosts, AR+ androgen-
responsive xenografts grown in the presence of continuous
testosterone supplementation expressed higher levels of
pAKT, pp38, and clusterin (Figure 5).
Finally, heat shock proteins HSP70, HSP27, and HSP90
have been shown by several authors to play a role in pro-
tecting cells from oxidative stress [27] and radiation [29].
However, we could not demonstrate, either in vitro or in vivo,
any differential effect of androgen on the level of expression
of any of these proteins. Thus, we speculate that androgens
could facilitate the expression of these stressmolecules in PC
cells only once oxidative stress has started to become a
threat. To test this, we preconditioned 22rv1 cells with 108 M
R1881, with 108 M R1881 + 105 M bicalutamide, or with-
out hormones (control) for 48 hours. This was followed by an
overnight incubation with 10 to 50 mM H2O2 for each condi-
tion. Although the expression of HSP70, HSP90, and HSP27
Figure 3. Androgens increase bROS levels in an AR-dependent manner.
In vivo effect on human PC xenografts. (A) In vivo expression of oxidative
stress– induced lipid peroxidation as detected by the presence of 4-HNE
protein adducts, judging by immunoblotting with anti –4-HNE antibodies.
WISH-PC23, WISH-PC14, and CWR22 xenografts were grown as subcuta-
neous tumors in castrated (androgen) or testosterone-supplemented
(androgen+) SCID mice. (B) In vivo expression of 8-OHdG in WISH-PC14,
WISH-PC23, and LuCAP-35 human PC xenografts grown as subcutaneous
tumors in castrated (A) or testosterone-supplemented (A+) SCID mice
(original magnification, 400).
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Figure 4. Androgens induce the activation and expression of stress proteins in 22rv1 cells that can be reverted by AD. (A) pAKT(ser473) expression. (B) pp38
expression. (C) pp38 activity as determined by the phosphorylation of the ATF-2 client protein. (D) Clusterin expression. (A–D) Lower panels show relative
expression in graphs. Results are derived from a minimum of three experiments and are expressed as mean ± SD. (E) The expression of HSP70, HSP27, and
HSP90 in 22rv1 cells is not differentially affected by androgen supplementation or deprivation, but is increased in response to oxidative stress (overnight incubation
with 50 M H2O2). CT = control cells growing in a culture medium with CSFCS and without phenol red; Bic = cells growing in the same medium but with the addition
of 10 M bicalutamide; T = cells growing in the same medium but with the addition of 10 nM R1881; T + Bic = cells growing in the same medium but with the
addition of both 10 nM R1881 and 10 M bicalutamide. Results are derived from at least three experiments and are expressed as mean ± SD.
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was increased by oxidative challenge, this did not depend
on the presence of androgens (Figure 4E ).
Effect of Androgens on the Expression and Activity
of Antioxidative Enzymes
We next examined whether AD causes a reduced ex-
pression and/or activity of several antioxidative enzymes.We
first elected to measure the antioxidative capacity of the cells
in a different hormonal milieu and found that androgens did
increase antioxidative capacity in a dose-dependent manner
(Figure 6A). Furthermore, blocking the AR with bicalutamide
could reduce antioxidative capacity, but this did not reach
statistical significance (P = .057) (Figure 6B).
Two key enzymes, MnSODand catalase, were also inves-
tigated to examine whether androgens regulate the expres-
sion of antioxidative enzymes. Expression of both enzymes
was significantly increased in androgen-supplemented cells
than in AD cells (P = .04 forMnSODandP = .004 for catalase,
respectively), and blocking of the AR with bicalutamide
significantly reduced their expression levels (P = .036 and
P = .004 for MnSOD and catalase, respectively) (Figure 6C).
Likewise, in vivo, all three AR+ xenografts that grew in the
Figure 5. In vivo effects of androgen supplementation and deprivation on the
expression of stress molecules and antioxidative enzymes. Androgens
induce in vivo activation of the stress molecules pAKT and p38, and the
expression of clusterin, the antioxidative enzyme MnSOD, and catalase, as
documented in three human PC xenografts: WISH-PC23, WISH-PC14, and
CWR22. These tumors were grown in castrated (androgen) or testosterone-
supplemented (androgen+) SCID mice. Note that the global expression of
pAKT and p38 is unchanged by androgen supplementation or deprivation, as
opposed to their activated (phosphorylated) forms.
Figure 6. Androgens increase the antioxidative capacity of 22rv1 cells. (A) Dose-dependent effect of R1881 on the antioxidative capacity of the cells. (B) AD, using
10 M bicalutamide, can reduce the antioxidative capacity of 22rv1 cells that are supplemented with 10 nM R1881. (C) The expression and activity of catalase and
MnSOD (D and E) in 22rv1 cells are significantly increased by androgen supplementation and are reduced by AD. (F) The activity of GR in 22rv1 cells is
significantly increased by androgen supplementation and is reduced by AD. Results are derived from at least three experiments and are expressed as mean ± SD.
CT = control cells growing in a culture medium with CSFCS and without phenol red; Bic = cells growing in the same medium but with the addition of 10 M
bicalutamide; T = cells growing in the same medium but with the addition of 10 nM R1881; T + Bic = cells growing in the same medium but with the addition of both
10 nM R1881 and 10 M bicalutamide.
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presence of continuous testosterone support expressed
higher levels of both enzymes compared to the same tu-
mors grown in castrated hosts (Figure 5). Furthermore, the
activity of both enzymes was significantly increased in cells
treated with R1881 compared to AD controls (P = .015 for
MnSOD and P = .022 for catalase) (Figure 6, D and E ). The
addition of bicalutamide to R1881 in the culture medium re-
duced the activity of both enzymes, but this was not statis-
tically significant. Compared to AD, physiological levels of
androgens significantly increased the activity ofGR (P= .032)
(Figure 6F ). Collectively, these results suggest that andro-
gens induce an increase in the antioxidative capacity of
AR-expressing PC cells, irrespective of their metabolic rate
and in an androgen-regulated manner that could be reversed
by AR blockade. This probably results from a dual effect:
increased expression of antioxidative enzyme and enhance-
ment of their activity.
Effect of Elevated Levels of bROS on Adaptive Response
to Oxidative Stress
Following the finding that androgens induce elevated
levels of bROS in an androgen-regulated manner, we exam-
ined whether this is the primary mechanism responsible for
acquired adaptation to oxidative stress challenge. To test
this, we incubated the cells following separate hormonal
preconditioning with the reducing agent N-acetylcysteine
(NAC) in an attempt to quench bROS. The levels of bROS
were reduced to an equal extent under all conditions of hor-
monal support by short-term preincubation with 5 mM NAC
(Figure 7A). Using this protocol, the differential effects of
R1881 on the expression of clusterin, pAKT(ser473), and
pp38 were no longer evident (Figure 7, B–D). In fact, there
was no difference in the expressions of these molecules
between control cells (no androgen), cells preconditioned
with R1881, and cells preconditioned with R1881 and bica-
lutamide. Collectively, this suggests that the induction of
elevated levels of bROS by androgens is the primary factor
responsible for the increased expression of these stress
proteins. Similarly, we also demonstrated that the expression
of MnSOD and catalase was directly dependent on bROS
levels. Short-term preincubation of the cells with 5 mM NAC
abolished the differential effects of androgen supplementa-
tion and AD on the expression of these enzymes (data not
shown). Intuitively, the androgen-induced increase in bROS
levels could also stimulate increased antioxidative enzyma-
tic activity; however, we did not test this, as incubation with
reducing agents such as NAC would naturally reduce the ac-
tivity of antioxidative enzymes.
Finally, we demonstrated that abolishing increased levels
of bROS (induced by androgens) by short-term pretreatment
with NAC eliminates the relative radioresistance of cells that
were preconditioned with R1881, bringing it to the same level
as cells that were preconditioned with AD (Figure 7E ),
whereas cells that were androgen-deprived were almost
three times more sensitive to 3-Gy g-radiation than the same
cells following pretreatment with 10 nM R1881 (mean sur-
viving fraction, 17.55% vs 49.3%; P < .001). The addition
of bicalutamide to R1881 increased cell killing by two-fold
(P = .0036). However, preconditioning also with NAC almost
equalized radiosensitivity across all hormonal treatments
(6%, 8.7%, and 8.1% surviving fraction for 10 mM bicalut-
amide, 10 nM R1881, and 10 mM bicalutamide + 10 nM
R1881, respectively). Thus, by reducing bROS levels under
all hormonal conditions, the net effect of NAC itself was to
sensitize the cells to radiation.
Discussion
The major finding here is that AD alters the redox environ-
ment of PC cells, thereby increasing their sensitivity to
radiation killing. This may strengthen the biologic rational
for adjuvant hormonal therapy, in combination with radiation,
in PC. We demonstrated that androgens induce adaptation
to oxidative stress challenge in PC cells. The development of
cellular adaptation to stress requires the acquisition of rela-
tive tolerance to it following exposure to lower levels of the
same stressor. Accordingly, adaptation of cells to oxidative
stress generally involves changes in the expression and/or
the activity of numerous cellular proteins that will prime the
cells with the ability to withstand more severe oxidative at-
tacks. Indeed, the generation of ROS leads to the stimulation
of various signaling pathways, such as mitogen-activated
protein kinases (MAPKs), and other stress-responsive pro-
tein kinases [30]. In particular, stress-responsive signal trans-
duction pathways are strictly regulated by the intracellular
redox state [31].
The framework of this study focused on proteins that are
recognized as playing an important role in the response of
tumor cells to radiation. Accumulating evidence suggests
that the phosphatidylinositide 3-kinase (PI3-K)–AKT signal-
ing pathway is a major contributor to radiation resistance.
As seen in patients with head and neck cancer who were
treated with radiation, a significant association was found
between positive pAKT immunostaining of tumors and local
control [32]. Furthermore, inhibition of AKT phosphorylation
at ser473 has recently been shown to sensitize tumors
to radiation, both in vitro and in vivo [33]. Inhibition of AKT1
with siRNA reduces tumor cell radiation survival, whereas
overexpression of exogenous AKT1 in AKT1 siRNA-treated
cells restores radiation sensitivity to baseline level [34]. Baron
et al. [35] showed that androgens can stimulate AKT phos-
phorylation through a direct interaction between the AR and
the p85a regulatory subunit of class I(A) PI3-K. Here, we
suggest that the androgen-induced phosphorylation of AKT
at the ser473 position is linked also to the fact that andro-
gens increase cellular levels of bROS that, by themselves,
trigger AKT phosphorylation, thereby enhancing cell survival
following oxidative injury. Notably, the expression levels of
nonphosphorylated AKT were not affected, in vitro (data not
shown) or in vivo (Figure 5), by androgens.
Activation of the p38 pathway is strongly related to stress,
with p38 being often referred to as a stress-activated protein
kinase. Low levels of oxidative stress tend to activate p38
transiently, as opposed to sustained activation of the protein,
which supports cell survival and not apoptosis [30]. The
activation of p38 kinase has been reported to protect cells
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from TNFa-induced apoptosis, which plays a role in apoptotic
response to radiation [36]. It has also been shown that p38
kinase can mediate AKT activation following UV radiation
[37], which also triggers oxidative challenge. Likewise, sev-
eral studies showed that an increased activity of p38 confers
a survival advantage on cells exposed to oxidative stress,
and that this can be induced by oxidative preconditioning of
the cells. Our results suggest that it is primarily the increase
in the oxidative status of the cells, rather than a direct
androgen-regulated effect, that triggers the increased ex-
pression of pp38 and its activity because preconditioning
with NAC (to reduce bROS levels) could ameliorate differ-
ences in the expression and activity of pp38 across different
hormonal manipulations (Figure 7D). Interestingly, Takada
et al. [38] showed that alteration of the redox status of
SK-OV-3 human ovarian cancer cells by MnSOD over-
Figure 7. The androgen-induced activation and expression of stress molecules and antioxidative enzymes stem from their induction by elevated bROS. (A)
Incubation with 5 mM NAC reduced bROS under all hormonal conditions. Upper figure: DHE fluorescent test (representative microscopic view of the DHE
fluorescence of 22rv1 cells in the presence and in the absence of R1881 and/or bicalutamide). Lower figure: Quantification of bROS levels (as measured with
confocal fluorescent microscopy) following normalization to the cells’ metabolic activity under different hormonal manipulations. Combined preincubation of 22rv1
cells with both R1881 and the reducing agent NAC erases the differential effects of different hormonal treatments on the expression of clusterin (B), pAKT(ser473)
(C), and pp38 (D). (E) Combined preincubation of 22rv1 cells with both R1881 and the reducing agent NAC abolishes relative resistance to radiation, which is
conferred to cells by androgens. Results show the survival of 22rv1 cells in a colony formation assay following a single treatment with 3-Gy radiation. CT = control
cells growing in a culture medium with CSFCS and without phenol red; Bic = cells growing in the same medium but with the addition of 10 M bicalutamide; T = cells
growing in the same medium but with the addition of 10 nM R1881; T + Bic = cells growing in the same medium but with the addition of both 10 nM R1881 and
10 M bicalutamide. Results are derived from at least three experiments and are expressed as mean ± SD.
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expression induced resistance to radiation by potentiating the
p38–MAPK pathway through ROS generation. The same
mechanism may be implicated here, as the levels of both
bROS and MnSOD were elevated in PC cells in vitro and
in vivo due to androgen stimulation. Interestingly, the expres-
sion levels of nonphosphorylated p38 were not influenced
in vitro (data not shown) or in vivo (Figure 5) by androgens;
thus, androgens (through their effect on bROS) appear to
exert their effect on the p38–MAPK pathway through the
activated form of the kinase.
Clusterin is a stress-associated cell survival molecule.
Gleave and Miyake [39] demonstrated that suppression of
clusterin levels using antisense oligonucleotides in PC cells
enhances killing following treatment with androgen ablation,
radiation therapy, and chemotherapy. Overexpression of
clusterin confers resistance to toxic oxidative membrane
damage in PC cells, especially in the presence of androgens
[28]. Our results clearly demonstrate that androgens in-
crease the expression levels of clusterin in vitro and in vivo,
as evident in four human PC models (22rv1, CWR22, WISH-
PC14, andWISH-PC23). An opposite phenomenon has been
reported in an immunohistochemical study using archival
radical prostatectomy specimens from 128 patients, some
of whom received neoadjuvant hormonal therapy [40]. The
clusterin expression in malignant prostate tissues was sig-
nificantly higher in patients who underwent preoperative
neoadjuvant hormonal therapy. However, this may reflect
stress-induced expression of clusterin resulting from hor-
monal deprivation of androgen-dependent PC, rather than
the fact that clusterin is an androgen-repressed gene. Indeed,
inhibition of castration-induced apoptosis by calcium channel
blockers in androgen-dependent Shionogi tumors prevented
clusterin gene upregulation, suggesting that clusterin is not
directly androgen-repressed but rather is regulated by apop-
totic stimuli [41]. In addition, it has been suggested that the
increased expression of clusterin in specimens from patients
who underwent AD mirrors part of the subsequent adaptive
increase in the expression of antiapoptotic genes [40].
The induction of heat shock proteins coincides with the
acquisition of tolerance to different kinds of cellular stress,
including oxidative stress [27]. Plaks et al. [27] showed inH5V
mouse embryonic endothelial cells that the acquisition of an
adaptive phenotype to oxidative stress is associated with the
expression of HSP70 and HSP27. We could not demonstrate
that androgens, by themselves, increase the expression of
either HSP70 or HSP27 in vitro or in vivo. Although we clearly
demonstrate that androgens significantly increase bROS
levels, this may not be a sufficient trigger for the induction
of HSP70 and HSP27 expression. Interestingly, even pre-
conditioning with both androgens and H2O2 could not induce
the differential expression of these heat shock proteins;
however, as expected, this did increase the global expression
of these heat shock proteins (as well as that of HSP90) under
all hormonal conditions (Figure 4E ). HSP90 is a molecular
chaperone involved in mediating cellular response to stress
and has a relatively high selectivity for several key molecules
such as Raf-1 and AKT, which are associated with protection
against radiation-induced cell death. In view of this, HSP90
inhibitors have been used in several tumor models, including
PC, to reduce the levels of multiple radioprotective regulatory
proteins, thereby increasing radiation sensitivity [42].
Another potential mechanism by which oxidative stress–
based therapies may be effective when combined with hor-
monal therapy is reduction in the expression and activity of
antioxidative enzymes because less ROS can be detoxified.
In the present study, wemeasured the expression and activity
of MnSOD and catalase (Figures 5 and 6, C–E ), as well as
the activity of GR (Figure 6F ). ROS, including superoxide, are
inevitably generated by a normal cellular metabolism, pri-
marily in the mitochondria as byproducts of the electron
transport chain. SOD, a group of metal-containing enzymes,
has a vital antioxidant role, catalyzing the dismutation of
superoxide—an anion very reactive to oxygen and H2O2.
Once formed, H2O2 must be reduced to water to prevent the
formation of toxic hydroxyl radicals. This is executed princi-
pally by catalase. Thus, SODs and catalase constitute the
first enzymatic line of defense in the detoxification of prod-
ucts resulting from the basal cellular production of ROS.
Supplementation of the culture medium with R1881 en-
hanced the antioxidative capacity of the cells (Figure 6, A
and B), increased the expression of MnSOD and catalase
(Figure 6C), and increased the activity of catalase, SOD, and
GR (Figure 6, C, D, and F ). Glutathione (GSH) is the most
abundant intracellular antioxidant, and intracellular redox
status is often measured by the ratio of GSH (reduced) to
oxidized glutathione (GSSG) [43]. Increased levels of intra-
cellular GSH correlate with radioresistance in vitro [44].
Accordingly, Husbeck et al. [45] radiosensitized human PC
cells by GSH depletion with selenite, thereby decreasing
GSH/GSSG ratio. In the present study, we demonstrated
that AD decreases the activity of GR (Figure 6F ), which is
responsible for the replenishment of GSH by the reduction
of GSSG. This could be another important mechanism by
which androgens induce adaptation to oxidative stress gen-
erated by ionizing irradiation.
In summary, we believe that AD therapy facilitates oxida-
tive stress–based therapies of PC by a dual mechanism
(Figure 8). Firstly, it may set lower levels of bROS in PC cells,
resulting in the reduced expression and activity of adaptive
stressmolecules. Secondly, it may also inhibit the expression
and activity of antioxidative enzymes and thus reduce cellular
antioxidative capacity. The effect of AD on the expression
and activity of antioxidative enzymes can be AR-mediated
and/or through reduced expression of bROS.
Although outside the scope of this study, we recognize
that another potential mechanism by which androgens can
induce adaptation to oxidative stress–based therapies may
be the induction of DNA repair systems [26,46], supporting
the practice of periodic continuation of AD even after the
completion of the radiation treatment course.
A potential future application of these findings is the ability
to use the expression profiles of pAKT, clusterin, pp38,
MnSOD, catalase, andGR as oxidative stress–related tumor
adaptation markers to triage patients with localized PC into
subgroups for refined preradiation prognosis criteria. Inter-
estingly, studies with human lymphocytes in vitro suggest
78 Adaptation to Oxidative Stress in Prostate Cancer Pinthus et al.
Neoplasia . Vol. 9, No. 1, 2007
that the human population is heterogeneous in its adaptive
response to ionizing radiation, whichmight, at least in part, be
genetically determined [47]. It is tempting to speculate that
the application of AD erases, to some extent, these differ-
ences by overcoming adaptive molecular barriers. A future
strategy would be to detect those PC patients who need
adjuvant AD with radiation, sparing it from all others.
In conclusion, we have demonstrated for the first time that
alteration of the intracellular redox state by androgens in PC
cells alters response to irradiation through the overexpres-
sion and increased activity of several stress kinases and
antioxidative enzymes. AD can antagonize these effects,
rendering AR-expressing PC cells more vulnerable to radia-
tion. These findings elucidate the clinical observation that
concomitant AD and radiation of localized PC confer thera-
peutic benefits.
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